College Pharmacy Incorporated, Colorado Springs, CO
Is College Pharmacy Incorporated registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does College Pharmacy Incorporated hold a Colorado pharmacy license?
The Colorado State Board of Pharmacy lists license PDO 240000038 for College Pharmacy, Colorado Springs, status Active, as of Nov 15, 2026. The Texas State Board of Pharmacy also lists nonresident license 25308 for COLLEGE PHARMACY, COLORADO SPRINGS, CO, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054016392 for COLLEGE PHARMACY, COLORADO SPRINGS, CO, status ACTIVE and license 054014294 for COLLEGE PHARMACY, COLORADO SPRINGS, CO, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000276 for COLLEGE PHARMACY, COLORADO SPRINGS, CO, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000645 for College Pharmacy, COLORADO SPRINGS, CO, status Active, as of Nov 10, 2026.
Has College Pharmacy Incorporated had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jul 19, 2022), 1 state handoff letter (Jul 19, 2022) and 1 FMD-145 letter (Jul 19, 2022) for College Pharmacy Incorporated. State board actions: record found. The Colorado State Board of Pharmacy’s license dataset lists 12 actions: “CLS Final Agency Order” dated Mar 16, 2018, case 2014-4027 on license PDO 240000038, “CLS Final Agency Order” dated Mar 16, 2018, case 2013-3563 on license PDO 240000038 and “CLS Combined w/other case for action” dated Mar 16, 2018, case 2014-4027 on license PDO 240000038, and 9 more listed below. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 5 actions: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for five years subject to the terms and conditions in the decision” dated Feb 21, 2024, case AC 7153 on nonresident license NRP 1034, “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Feb 21, 2024, case AC 7153 on nonresident license NSC 99550 and “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Feb 21, 2024, case SI 7358 on nonresident license NSC 99550, and more listed below. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Probation” dated Apr 26, 2011, case 2009012647 on nonresident license 054016392. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- College Pharmacy Incorporated
- Location
- Colorado Springs, CO
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jul 19, 2022
- FDA Data Dashboard inspections
- 4 inspections: 3 OAI, 1 NAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 19 observations
- State board records
- License found: PDO 240000038, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as College Pharmacy Incorporated, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jul 19, 2022 | State handoff letter | State Handoff Letter Issued 7/19/2022 | Not linked by FDA |
| Jul 19, 2022 | Warning letter close-out | Warning Letter Closeout Issued 7/19/2022 | Not linked by FDA |
| Jul 19, 2022 | FMD-145 letter | FMD-145 Letter Issued 07/19/2022 | Not linked by FDA |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists College Pharmacy, Inc., Colorado Springs, CO (FEI number 1000117234), matched to this page by exact name, city and state. It lists 4 inspections: 3 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 15, 2021 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 1000117234 | 1158430 |
| Jan 17, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1000117234 | 1038075 |
| May 28, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1000117234 | 926643 |
| Mar 15, 2013 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI); Human Cellular, Tissue, and Gene Therapies (Biologics): Official Action Indicated (OAI) | 1000117234 | 823528 |
Form 483s FDA has published for this site
- Feb 21, 2018: Form 483 to College Pharmacy, Inc., published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to College Pharmacy, Inc., published Jan 17, 2024. fda.gov
- Jul 10, 2015: Form 483 to College Pharmacy, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 19 numbered observations in all, across 3 inspections ending Mar 15, 2013 to Jan 17, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jan 8, 2018 to Jan 17, 2018: 6 observations
- Firm on the cover
- College Pharmacy, Inc., 3505 Austin Bluffs Parkway, Suite 101, Colorado Springs, CO 80918-5754
- FEI number
- 1000117234
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Specifically,
a.) Actionable microbial contamination was discovered inside the ISO 5 aseptic processing environment on two occasions via viable air samples; however, no evaluation of product impact was made. For example:
017@1.
i. On 07/12/17, a viable air sample was collected from the ISO 5 <Redacted B4> Hood <Redacted B4> which re sul ted in an a ctionable envi ronmental exc ursi on of o ne colon y for ming unit i den tified as Bacillus me gate rium. Th e fom did not eva luate any produc ts fill ed i n the IS O 5 Hoods on 07/ 12/17 fo r produc t i mpact, to include: Cellul ite Pr es. 10ml Hom eopathic In ject ion, lot 0712 2017@50; Muscle/ Skelet al Pr es. ...
Observation 2
You produced highly potent drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically, the firm uses <Redacted B4> and <Redacted B4> to clean the shared hoods and equipment used to manufacture different sterile hormonal implantable pellets, to include estradiol, progesterone, pregnenolone, testosterone, and dehydroepiandrosterone (DHEA). There is no assurance that the cleaning materials used prevent cross-contamination between these products.
progesterone, pregnenolone, testosterone, and dehydroepiandrosterone (DHEA). There is no assurance that the cleaning materials used prevent cross-contamination between these products.
Observation 3
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, on 01/08/18 and 01/09/18, we observed the Pharmacy Technician/Aseptic Operator touch the outside surface of the sterile gown arms and sterile hood with bare hands while gowning in the ISO 7 Ante Room. Moreover, the legs of the sterile gown touched the floor during gowning. The Pharmacy Technician/ Aseptic Operator proceeded to conduct aseptic filling operations and was observed inserting his arms into the ISO 5 hood to aseptically fill sterile drug products and leaning into the ISO 5 hood, head included, to observe the fill level of vials. The following products were observed being filled these two days: DPN/NAD+ PF 100mg/ml Injection, lot 01082018:15@7; Dimethyl Sulfoxide Modified Pres. 6.25% Ophthalmic, lot 01082018:41@6; Vitamin D3 PF 50,000IU/ml Injection, lot 01082018:00@9; Ammonium Glycyn:hizinate Pres. 8.33mg/ml Injection, lot 01092018:46@1; and B Complex 100 PF Injection, lot 01092018:38@4.
Additionally, bare hands are placed inside the ISO 5 hoods to don sterile gloves.
Observation 4
Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, non-sterile <Redacted B4>. Disinfectant Cleaner, lot <Redacted B4> is the disinfectant currently in use for <Redacted B4> cleaning of ISO 5 hoods and surfaces used in the production of sterile injectable and ophthalmic drug products.
Observation 5
The ISO 5 classified aseptic processing areas had difficult to clean and particle-generating equipment or surface.
Specifically, not all the materials brought into the ISO 5 hood are easily cleanable or non-paiticle shedding. For example:
a.) On 01/09/18, we observed the aseptic filling of Anunonium Glycyrrhizinate Pres. 8.33mg/ml Injection, lot 01092018:46@1, in ISO 5 <Redacted B4> Hood ID: <Redacted B4> which involved the filling of 5ml vials in the vial supplier's original paperboard-like packaging container, which is paiticle shedding.
b.) On 01/10/18, we observed the set-up and aseptic filling of Ascorbic Acid <Redacted B4> Source 500mg/ml Injection, lot 01102018:48@2, in ISO 5 <Redacted B4> Hood ID: <Redacted B4> which involved the use of clear prescription label tape to affix a plastic container on the back of the repeater pump to prevent spillage, and yellow label tape to keep the lid of the repeater pump closed. Both tapes are not easily cleanable and not designed for use in an ISO 5 aseptic production environment.
Observation 6
You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contaimination.
Specifically, you do not adequately clean the glassware and utensils used to produce sterile drug products to prevent cross-contamination. There is no sterilization or depyrogenation activities performed on these materials prior to use in compounding sterile drug products. For example:
a.) Glassware, spatulas, and Inixing bars are washed in a dishwasher using <Redacted B4> dishwasher detergent.
b.) Plastic graduated cylinders are washed in the sink using <Redacted B4> dishwashing liquid.
Inspection May 11, 2015 to May 28, 2015: 7 observations
- Firm on the cover
- College Pharmacy Incorporated, 35 05 Au stin Bl uffs Pk wy St e 10 1, Colorado Springs, CO 80918-5754
- FEI number
- 1000117234
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087), Denver, CO 80225-0087,
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Regardless of the number of cfu detected during environmental monitoring of the pharmacy, identification of microorganisms recovered is not always conducted in order to assess whether corrective/preventative actions should be undertaken should pathogenic microorganisms be found. For example, gloved fingers sampled on 3/11/2015 found 2 cfu but the microorganisms were not identified. Gloved fingers sampled on 8/27/2014 found 1cfu but the microorganisms were not identified.
Also, although smoke studies are reported to have occurred under dynamic conditions, there are no established procedures for conducting documented smoke studies (e.g., review/conclusion whether acceptable) in order to show proper design and control in preventing turbulence and stagnant air in aseptic processing areas. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
_Cl.AJE ISSU!iO
performed. Similarly, Media Fill to simulate the aseptic filling of eye drops is not conducted. There are [Redaction (b)(4)] of sterile filling [Redaction (b)(4)] [Redaction (b)(4)]. This method for simulating sterile filling (of lyophllized Glutathione, HCG, and DPN Inj) does not have a Media Fill performed, nor does the sterile filling of eye drops, such as Glutathione/Vitamin C/DMSO Ophthalmic Soln.
The lyophilization process is not adequate to protect product, as it is partly performed in ISO 7 classified air. Specifically,
compoun ded drugs (such as Glutathione, HCG, and DPN) are [Redaction (b)(4)] lyophilization process [Redaction (b)(4)].
Except for compounded drug pellets, there is no bioburden testing of product formulations (e.g., such as Glutathione/Vitamin C/DMSO Ophthalmic Soln.) intended to be sterilized, nor have limits for bioburden been established to ensure that [R
ed action (b)] [Redaction (b)(4)] used to produce finished drug products are adequate.
Observation 3
Test procedures relative to appropriate laboratory testing for sterility are not written.
When conducting sterility test ing of injectable products compounded at your pharmacy using your in-house laboratory: When conducting sterility testing of injectable products compounded at your pharmacy using your in-house laboratory:
a) growth promotion tests of aerobes, anaerobes and fungi of each lot of ready-prepared media is not conducted at receipt to ensure that it will encourage growth, i.e., the media selected is not demonstrated at your facility to support growth of gram negative & gram-positive bacteria, yeast and mold.
b) method suitability testing of this sterility test method was only conducted on two of your compounded products.
c) should a compounded drug be found not to comply with this test for sterility, your firm has no Out-of-Specification procedures to ensure proper evaluation of results that fall outside of specifications.
d) your firm does not have written and approved procedures for performing sterility testing.
You have been doing sterility testing at your in-house laboratory since about 20 11. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically, although sterilized [Redaction (b)(4)] is used to sanitize surfaces of the ISO 5 LAFWs, the wipes used in unison with the [Redaction (b)(4)] to sanitize ISO 5 LAFWs are not sterile.
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Analytical methods used for assay analyses of drugs are not always validated (i.e., the accuracy, sensitivity, specificity, and reproducibility of test methods have not been established). For example, assays run by contracted laboratories for HCG, Glutathione, Testosterone and Pyridoxine were tested with analytical methods not validated. For example, a Certificate of Analysis report from [Redaction (b)(4)] concerning amino acid assay testing [Amino Acid (Recover Eaze) IV Formula PF Inj] conducted for your firm states, in part, "The method(s) used for testing are not validated."
There is not complete testing of drug pellets containing testosterone, estradiol, and other hormones, compounded for subcutaneous insertion. These drugs are intended for 3 month release but there is no data to support that these drugs are released into the body in a safe, controlled, regulated and effective manner.
Observation 6
Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit. y
Allergenic Extracts used for compounding are not always obtained from FDA-licensed distributers/manufacturers (such as [Redaction (b)(4)].
0All;IS6UEO
Observation 7
Clothing of personnel engaged in the processing and packing of drug products is not appropriate for the duties they perform.
Sterile gloves are used, but other sterile gowning components (such as sterile suits, sterile face masks, sterile hoods, and goggles) are not utilized by personnel when aseptically filling compounded products in your clean (buffer) room.
Clean room personnel are donning non-sterile suits, face masks, and hoods for operations in the clean room and ISO 5 [Redaction (b)(4)] laminar t1ow clean benches, performing aseptic manipulations of finished drug product vials. There are no procedural requirements for comprehensive sterile gowning (other than just gloves) to prevent contamination during aseptic manipulations.
Gowning (e.g., suits, face masks, gloves and hoods) that is employed (observed on 5/11/2015) does not completely cover skin, leaving areas of the face exposed (goggles are not used).
Inspection Mar 5, 2013 to Mar 15, 2013: 6 observations
- Firm on the cover
- College Pharmacy I ncorporat ed, 3505 Austin Bluffs Parkway Suite 101, Colorado Spring s, C O 8 0918 Producer of St e rile Dr ug Product s
- FEI number
- 1000117234
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing ofdrug products.
Specifically, the firm does not have documentation supporting the design and maintenance ofthe facility to ensure the high quality air required for the production ofthe sterile products.
1) T he area designated as the clean room and identified by the firm as being classified with ISO 5 and ISO 6 areas has b een modified structually and is not supported by continuous monitoring data to be considered a classified area for sterile drug production. For example: ·
a. The clean room HEPA recertification is performed redacted (b)(4) redacted (b)(4); however, the recertification does not include leak testing. The firm also has no documentation supporting that leak testing has ever been performed. In addition, each of the classified rooms (including the ISO 7 growning room located immediately outside of the clean room) was recertified at static conditions only. No dynamic evaluations have ever been performed and no active or non-active particulate monitoring is routinely performed outside of the redacted (b)(4) review. a. ...
Observation 2
Each batch ofdrug product required to be free ofobjectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, the firm's current sterility testing methods for prepared sterile drug products are not being completed in accordance to their written procedure SOP 11.050.2 in that their sample size does not match what is required by the procedure and is not sufficient to be representative ofthe batch ofsterile product produced. In addition, their formula worksheets contain spaces for sample documentation, but do not specify how much sample should be tested by the sterile processing employee. There is also no documentation for how much sample was actually selected for testing. For example:
1) The Formula Worksheet for EDT A/Mag Sulfate PF 3 gm/lgm/20ml injectable involves the production of redacted (b)(4) x 100
ml vials ofthe preservative free sterile product. Although not specified on the sampling section ofthe form, 3 x I ml each was tested by the firm for sterility assurance. The sample size according to their procedure should have been redacted (b)(4) mls from each of redacted (b)(4) x 100 ml vials. ...
Observation 3
Each lot ofa component liable to objectionable microbiological contamination is deficiently subjected to microbiological tests before use.
Specifically, the firm's Sterility Supervisor stated that they use approximately 99% non-sterile raw materials to produce s terile finished injectable products relying on their sterile r edacted (b)(4) methods to ensure prod uct sterility. Proper use of sterile redacted (b)(4) methods depends on their evaluation of the material which they are redacte
d (b)(4) and they have not routinely challenged certificates of analysis provided by raw material suppliers prior to utilizat ion in sterile production of their drug products. Additionally, the firm has never performed bioburden studies or have established limits for bioburden to ensure that the redacted (b)(4) methods used for their finished products are adequate for their sterile processing operations.
used for · finished
Specifically, the firm's Sterility Supervisor stated that they use approximately 99% non-sterile raw materials to produce sterile finished injectable products relying on their sterile redacted (b)(4) methods to ensure product sterility. ...
Observation 4
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile do not include validation ofthe sterilization process.
Specifically,
1) P ersonnel qualification for sterile processing is delineated in the firm's written procedure, SOP 11.010.2, which i ncludes redacted (b)( 4) media fills. On 3/7/13, during the inspection I observed the media fill proces s and noted the following:
a. The firm uses production c;mmuv"" use to ensure that it is caJ>able
in performing the media fill which is produced by the their
a. The firm u ses redacted (b)(4) in performing the media fill which is produced by the their production employee using redacted (b)(4); however, the redacted (b)(4) is never challenged prior to use to ensure that it is capable of growing aerobic bacteria.
b. In accordance with SOP11.010.2, and the associated written procedure titled "Media Fill Test for Aseptic
Technique 3% Solution Liq", the maximum number ofmanipulations within the clean room environment during media fill qualification is redacted (b)(4). ...
Observation 5
There is no written testing program designed to assess the stability characteristics ofdrug products.
Specifically, the finn does not have a stability testing program in place for the more than 5,000 different products produced at their facility, including sterile injectable products. They also do not have a formal change control process to assist in delineating when more recent stability tests have to be conducted and their Sterility Supervisor has stated that product stability testing (including assay) is only performed on product redacted (b)(4) after they have established a beyond use date (BUD). For example:
EMPlOYEJ: S) StGNAlVRe DATEISSUEO
generated any current data supporting a 180 day BUD despite the five stability failures that preceded (including failures in 2005, 2006, 2007, and 2008). Their Sterility Supervisor has stated that the firm had dispensed EDT A/Mag Sulfate from these failed batches as they do not always perform analytical testing for potency prior to distribution.
Additionally, the firm does not perform routine ongoing stability testing to ensure that current data continues to support
beyond use dates. For example: ...
Observation 6
Testing and release ofdrug product for distribution do not include appropriate laboratory determination ofsatisfactory conformance to the final specifications and identity and strength ofeach active ingredient prior to release.
Specifically, the finn does not have a written established program and does not conduct routine analytical evaluation ofthe products produced at their facility for identification or potency of each batch ofproduct produced prior to dispensing to end users.
State board of pharmacy records
The Colorado State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PDO 240000038 | PDO | College Pharmacy | Colorado Springs | Active |
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Mar 16, 2018: “CLS Final Agency Order”, license PDO 240000038, case 2014-4027, College Pharmacy, Colorado Springs, CO. Board document
- Mar 16, 2018: “CLS Final Agency Order”, license PDO 240000038, case 2013-3563, College Pharmacy, Colorado Springs, CO. Board document
- Mar 16, 2018: “CLS Combined w/other case for action”, license PDO 240000038, case 2014-4027, College Pharmacy, Colorado Springs, CO. Board document
- Jul 22, 2013: “CLS Letter of Admonition”, license PDO 240000038, case 2013-869, College Pharmacy, Colorado Springs, CO. Board document
- Apr 10, 2009: “CLS Combined w/other case for action”, license PDO 240000038, case 2009-1779, College Pharmacy, Colorado Springs, CO. Board document
- Apr 10, 2009: “Stipulation”, license PDO 240000038, case M2009-639, College Pharmacy, Colorado Springs, CO. Board document
- Dec 18, 2007: “CLS Stipulation”, license PDO 240000038, case 2008-569, College Pharmacy, Colorado Springs, CO. Board document
- Oct 19, 2007: “ITRM Summary Suspension”, license PDO 240000038, case 2008-569, College Pharmacy, Colorado Springs, CO. Board document
- Oct 19, 2007: “ID Hearing Formal Complaint/Charges Filed with OAC”, license PDO 240000038, case 2008-569, College Pharmacy, Colorado Springs, CO. Board document
- Dec 21, 2005: “Stipulation”, license PDO 240000038, case M2004-55, College Pharmacy, Colorado Springs, CO. Board document
- Dec 21, 2005: “CLS Combined w/other case for action”, license PDO 240000038, case 2005-4152, College Pharmacy, Colorado Springs, CO. Board document
- Apr 7, 2004: “CLS Stipulation”, license PDO 240000038, case 2004-838, College Pharmacy, Colorado Springs, CO. Board document
What this covers: Discipline the Department of Regulatory Agencies publishes with each license in the dataset (case number, program action and effective date), worded as the department gives it. Actions in the data are dated Oct 11, 1985 to Oct 30, 2026.
Nonresident licenses and board actions in other states
These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.
Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).
| License | Type as the board gives it | Name on the board record | Location | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 25308 | Non Resident Sterile Compounding | COLLEGE PHARMACY | COLORADO SPRINGS, CO | Active | Yes |
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
- Feb 21, 2024: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for five years subject to the terms and conditions in the decision.”, license NRP 1034, case AC 7153, College Pharmacy, Colorado Springs, CO. Board list
- Feb 21, 2024: “Through a disciplinary action of the Board, the license is voluntarily surrendered.”, license NSC 99550, case AC 7153, College Pharmacy, Colorado Springs, CO. Board list
- Feb 21, 2024: “Through a disciplinary action of the Board, the license is voluntarily surrendered.”, license NSC 99550, case SI 7358, College Pharmacy, Colorado Springs, CO. Board list
- May 6, 2020: “Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the license is placed on probation for two years subject to the terms and conditions in the decision.”, license NRP 1034, case AC 6461, College Pharmacy, Colorado Springs, CO. Board list
- May 6, 2020: “Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the license is placed on probation for two years subject to the terms and conditions in the decision.”, license NSC 99550, case AC 6461, College Pharmacy, Colorado Springs, CO. Board list
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054016392 | LICENSED PHARMACY | COLLEGE PHARMACY | COLORADO SPRINGS, CO | ACTIVE |
| 054014294 | LICENSED PHARMACY | COLLEGE PHARMACY | COLORADO SPRINGS, CO | CHANGE OF OWNERSHIP |
- Apr 26, 2011: “Probation”, license 054016392, case 2009012647, COLLEGE PHARMACY, COLORADO SPRINGS, CO. Reason given in the record: “after its Colorado pharmacy license having been placed on probation for a period of seven years on or about April 10, 2009, related to the pharmacy's compounding activities under a previous owner and pharmacist-in-charge.” Board list
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0000276 | NONRESIDENT PHARMACY | COLLEGE PHARMACY | COLORADO SPRINGS, CO | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0000645 | Non Resident Pharmacy | College Pharmacy | COLORADO SPRINGS, CO | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- Texas State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Texas State Board of Pharmacy disciplinary records
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.